Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition(s):Lymphoma; T-Cell Lymphoma; Cutaneous LymphomaLast Updated:June 9, 2020Completed